JCARH125, Anti-BCMA CAR T-cell Therapy for Relapsed/Refractory Multiple Myeloma: Initial Proof of Concept Results from a Phase 1/2 Multicenter Study (EVOLVE)
Sham Mailankody(Memorial Sloan Kettering Cancer Center), Andrzej Jakubowiak(University of Chicago Medical Center), Myo Htut(City Of Hope National Medical Center), Kelvin P. Lee(Roswell Park Comprehensive Cancer Center), Safiyyah Ziyad(Bristol-Myers Squibb (United States)), John Byon, William Bensinger(Swedish Medical Center), Todd DeVries(Unknown), Julia Piasecki(Université Paris Cité), Michelle Blake(Moderna Therapeutics (United States))
Cited by 124
Related Papers
Methotrexate and Cyclosporine Compared with Cyclosporine Alone for Prophylaxis of Acute Graft versus Host Disease after Marrow Transplantation for Leukemia
|New England Journal of Medicine|1986|1.5k
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
|New England Journal of Medicine|2023|695
Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval
|JAMA Internal Medicine|2017|497
The high price of anticancer drugs: origins, implications, barriers, solutions
|Nature Reviews Clinical Oncology|2017|430